Hormone receptor-positive (HR+) breast cancers take up 80% of total breast cancers, which can be treated with adjuvant hormone therapy (AHT) after surgery and chemotherapy to prolong survival and lower the risk of breast cancer recurrence [2]. Here, NR4A1 is linked to breast carcinoma.